^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Prolia (denosumab) (RANK ligand inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1409P - DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after first-line immunotherapy: A prospective, single-arm, phase II trial (DEMAIN)
Published date:
10/16/2023
Excerpt:
Eligible pts had advanced KRAS-mutated NSCLC and were receiving first-line PD-1 inhibitor-based therapy. Pts were treated with PD-1 inhibitor (q3w) and denosumab (120 mg, q4w) for subsequent maintenance therapy regardless of bone metastases….Subgroup analysis suggested a greater survival benefit in patients with KRAS G12C mutation than in patients with KRAS non-G12C mutation (mPFS1, p=0.026; mPFS2, p=0.049).
Secondary therapy:
PD-L1 inhibitor
